Privileged and Confidential

November 13, 2018

Office of the Vermont Attorney General

Re: New Drug Price Report Pursuant to 18 V.S.A. § 4637

On September 28, 2018, the FDA approved Libtayo® (cemplimab-rwlc) for the treatment of patients with metastatic cutaneous squamous cell carcinoma (CSCC) or locally advanced CSCC who are not candidates for curative surgery or curative radiation.

Regeneron is providing you with the following information as required by 18 V.S.A. § 4637 in connection with Libtayo (cemplimab-rwlc).

- The marketing and pricing plans in connection with the launch of Libtayo in the U.S. and internationally are not in the public domain, not publicly available, and are confidential.
- The estimated number of patients who may be prescribed Libtayo is not in the public domain, not publicly available, and is confidential. Note however that it is estimated that CSCC is responsible for approximately 7,000 deaths each year.
- FDA granted Libtayo both breakthrough therapy and priority review designation status.
- Libtayo was invented and developed by Regeneron.

Please feel free to contact me if you have any further questions.

Kaelyn Buck, Pricing

Regeneron Pharmaceuticals Inc. | 1 Rockwood Road, Sleepy Hollow, NY 10591

Cell: 914.839.2048 |Office: 914.847.3357 | kaelyn.buck@regeneron.com